UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.

•Long-term outcome was not different between the anthracycline and the concomitant taxane and anthracycline regimens.•In the human epidermal growth factor receptor-2 population, long-term results are in line with those of the other adjuvant trials.